Clinical trials: Diabetes Type I
Diabetes Mellitus
Insulin Glulisine, Insulin Lispro and Insulin Glargine in Type 1 or 2 Diabetes Mellitus
Primary: To compare the efficacy and safety of Insulin Glulisine to Insulin Lispro in subjects with type 1 or type 2 diabetes mellitus. To compare the frequency of hypoglycemia of Insulin Glulisine to Insulin Lispro.
- Trial name
- NCT00467376
- Testing
- Insulin Glulisine, Lispro, Insulin Glargine
- Where
- China
- Volunteers
- 485 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DS-1150b in Healthy Subjects and Subjects With Type-2 Diabetes Mellitus
DS-1150b is being developed by Daiichi Sankyo for the treatment of Type 2 Diabetes Mellitus. This is a Phase I, single-blind (subjects and principal investigator blinded, Sponsor unblinded), placebo-controlled, randomized…
- Trial name
- NCT02004678
- Testing
- DS-1150b
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Daiichi Sankyo
Type 2 Diabetes, Nephropathy
A Research Study to Evaluate the Renal (Kidney) Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes (0954-147)(COMPLETED)
Evaluate the effect of Losartan in reducing kidney disease in patients with Non-insulin Dependent Diabetes and Nephropathy (kidney damage that usually accompanies late stage Diabetes Mellitus).
- Trial name
- NCT00308347
- Testing
- MK0954, losartan / Duration of Treatment: mean 3.4 years
- Volunteers
- 1,513 people
- Sponsor
- Organon and Co
Hypoglycemia
Glucagon Ready-to-Use (RTU) for Prevention of Exercise-Induced Hypoglycemia During Aerobic Exercise in Adults With T1D
This study is a randomized, placebo-controlled, double-blind, 2-treatment, 2-period, crossover comparison in a clinical research center (CRC) setting, followed by a randomized, placebo-controlled, double-blinded, 2-arm parallel…
- Trial name
- NCT03841526
- Testing
- Glucagon RTU Injection With Insulin Pump Reduction, Vehicle for Glucagon RTU Injection With Insulin Pump Reduction, Glugaon RTU Injection Without Insulin Pump Reduction
- Where
- Canada
- Volunteers
- 48 people
- Sponsor
- Xeris Pharmaceuticals
Diabetes, Diabetes Mellitus, Type 1
Comparison of the Effect of NN5401 With the Effect of NN1250 and Insulin Aspart in Subjects With Type 1 Diabetes
This trial is conducted in Europe. The aim of this trial is to compare the blood glucose-lowering effect of NN5401 (insulin degludec/insulin aspart, IDegAsp) with NN1250 (insulin degludec, IDeg) and insulin aspart (IAsp) in…
- Trial name
- NCT01173926
- Testing
- insulin degludec, insulin degludec/insulin aspart, insulin aspart
- Where
- Germany
- Volunteers
- 27 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus
Primary Objective: To compare the efficacy of a new formulation of insulin glargine (HOE901-U300) to Lantus in terms of change of HbA1c from baseline to endpoint (month 6) in children and adolescents with type 1 diabetes…
- Trial name
- EDITION JUNIOR (NCT02735044)
- Testing
- Insulin glargine,300 U/mL, Insulin glargine (100 units /mL), Background therapy
- Where
- 107 sites in United States, Argentina and 22 more
- Volunteers
- 463 people
- Sponsor
- Sanofi
Diabetic Retinopathy, Diabetic Macular Edema
Prevalence of DIAbetic RETinopathy and Impact of Genetic Factors in the Development of Diabetic Retinopathy of Patients With Type 1 and 2 Diabetes Mellitus in SlovaKia
The aim of the study is to find out prevalence and individual stages of Diabetic Retinopathy in patients with type 1 and type 2 DM verified based on complex ophthalmologic measurements in Slovak Republic.
- Conditions
- Diabetic Retinopathy, Diabetic Macular Edema, Diabetes Mellitus
- Trial name
- DIARET SK (NCT02232503)
- Testing
- Studied cohort
- Volunteers
- 4,011 people
- Sponsor
- Novartis Slovakia, s.r.o.
Diabetes, Diabetes Mellitus, Type 1
A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in India
This study is conducted in Asia. The aim of this observational study is to evaluate the current status of diabetes management, control, and complications in diabetic subjects in India.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- DiabCare India (NCT01351922)
- Testing
- No treatment given
- Where
- India
- Volunteers
- 12,000 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus
French Prospective Multicentric Study in Real World
The purpose of this postmarket clinical investigation is to evaluate the levels of glycemic control, quality of life, and satisfaction, as well as the patient experience, and acute diabetes complication rates provided by the…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1 Diabetes
- Trial name
- OPTIMAL-A (NCT07039942)
- Testing
- Omnipod 5
- Where
- 24 sites in France
- Volunteers
- 304 people
- Sponsor
- Insulet Corporation
Diabetes Mellitus, Type 1
Trial of Otelixizumab for Adolescents and Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-2
DEFEND-2 is a Phase 3 confirmatory study for the Phase 3 DEFEND-1 study. The study objective is to find out if an 8-day series of otelixizumab infusions leads to greater improvement in insulin secretion as compared with placebo.
- Trial name
- DEFEND-2 (NCT01123083)
- Testing
- Otelixizumab
- Where
- Italy
- Volunteers
- 179 people
- Sponsor
- GlaxoSmithKline
Type 1 Diabetes Mellitus
Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus
The primary purpose of this study is to determine whether teplizumab (MGA031) infusions lead to greater reductions in insulin requirements in conjunction with near normal blood sugar control compared to placebo in patients…
- Trial name
- NCT00920582
- Testing
- Teplizumab Herold Regimen, Teplizumab 33.3% Herold Regimen, Teplizumab Curtailed Herold Regimen
- Where
- 118 sites in United States, Belgium and 14 more
- Volunteers
- 254 people
- Sponsor
- MacroGenics
Diabetes, Diabetes Mellitus, Type 1
The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes
This trial is conducted in Africa, Europe and North America. The purpose of the trial is to investigate the efficacy and safety of liraglutide adjunct to insulin treatment in type 1 diabetes.
- Trial name
- ADJUNCT TWO™ (NCT02098395)
- Testing
- liraglutide
- Where
- 120 sites in United States, Austria and 11 more
- Volunteers
- 835 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
Renal and Peripheral Hemodynamic Function in Patients With Type 1 Diabetes Mellitus
Protein kinase C (PKC), an enzyme in the body, has been implicated in the process of diabetic microvascular complications. The purpose of this study will be to evaluate the renal hemodynamic and peripheral vascular effects of PKC…
- Trial name
- NCT00297401
- Testing
- ruboxistaurin
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Chromaderm, Inc.
Diabetes, Diabetes Mellitus, Type 1
Comparison of Two NN1250 Formulations in Subjects With Type 1 Diabetes
This trial is conducted in Europe. The aim of the trial is to investigate the pharmacodynamic properties (effect) by comparing two NN1250 (insulin degludec, IDeg) formulations in subjects with type 1 diabetes.
- Trial name
- NCT01076634
- Testing
- insulin degludec
- Where
- Austria
- Volunteers
- 33 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus: Type 1
A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin Lispro
28 subjects to be enrolled for a screening period, 3 dosing visits \& a follow-up visit. Visits 2 and 3 dosing of TI Inhalation Powder, cross over between two 15 U cartridges and one 30 U cartridge.
- Trial name
- NCT00662857
- Testing
- Technosphere® Insulin Inhalation Powder, Technosphere Insulin® Inhalation Powder, RAA Population
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Mannkind Corporation
Diabetes Mellitus Type 1
ZP4207(Dasiglucagon) Administered to T1D Patients to Assess the PK and PD Compared to Marketed Glucagon
The trial is a single-centre, randomised, sequential, cross-over trial assessing pharmacokinetic and pharmacodynamic responses after micro-doses of ZP4207 (dasiglucagon*) administered subcutaneously to patients with type 1…
- Trial name
- NCT02916251
- Testing
- ZP4207(dasiglucagon) glucagon analogue, Glucagon (Native glucagon)
- Where
- Germany
- Volunteers
- 38 people
- Sponsor
- Zealand Pharma
Type 1 Diabetes
Study of the Effects of XOMA 052 on Insulin Production in Subjects With Well Controlled Type 1 Diabetes
The study hypothesis is that XOMA 052 may inhibit beta-cell destruction and enhance beta-cell regeneration. The purpose of this study is to assess the effects of XOMA 052 on beta-cell function and insulin production.
- Trial name
- NCT00998699
- Testing
- Xoma 052
- Where
- 2 sites in Switzerland
- Volunteers
- 22 people
- Sponsor
- XOMA (US) LLC
Diabetes, Diabetes Mellitus, Type 1
A Trial Investigating the Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec/Insulin Aspart 15 in Subjects With Type 1 Diabetes
This trial is conducted in Europe. The aim of the trial is to investigate the pharmacodynamic (the effect of the investigated drug on the body) and the pharmacokinetic (exposure of the trial drug in the body) properties of…
- Trial name
- NCT01773798
- Testing
- insulin degludec/insulin aspart 15, insulin degludec/insulin aspart, insulin degludec
- Where
- Austria
- Volunteers
- 33 people
- Sponsor
- Novo Nordisk A/S
Type I Diabetes
Clinical Evaluation of the Medtronic Implantable Insulin Pump System (MIIPS 2020) in Adult Subjects With Type 1 Diabetes (CIP347)
The purpose of this study is to evaluate the clinical performance of the Medtronic Implantable Insulin Pump System (MIIPS 2020) in adult patients with Type 1 diabetes mellitus that cannot be controlled with subcutaneous insulin…
- Trial name
- Phoenix CIP347 (NCT06739811)
- Testing
- Implantable Insulin Pump System
- Where
- 11 sites in France, Netherlands
- Volunteers
- 40 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Study to Evaluate a Prototype Non-Invasive BG Measurement System
1. Diabetes mellitus is a chronic disease currently affecting more than 425 million people, of which one-third are people older than 65 years.
- Trial name
- ATD (NCT05023798)
- Testing
- ATD (device test)
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- Afon Technology
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.